← Leaderboards
Willem Van Schooten
Teneobio, Inc.
$1,701,500
Attributed
$1,701,500
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $889.3K · FY2018–20$1M$750K$500K$250K$0
'18
'19
'20
Funding mix
By agency
NIH$1,701,500 · 6
By mechanism
R43$1,701,500 · 6
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “In Vivo”
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,216,744
- Leonard Freedmand · Leidos Biomedical Research, Inc.$66,248,714
- John Damon Chodera · Sloan-Kettering Inst Can Research$43,427,103
- Tony Moody · Duke University$34,777,314
- Alan D. Palkowitz · Indiana University Indianapolis$18,925,366
Research focus
In VivoBindingAffinityFamilyAntibodiesBaseFutureIn VitroImmuneEffective TherapyT-LymphocytePhase I Clinical TrialsTherapeutic AntibodiesAnimalsCellsSafetyImmunizeClinicRattusSpecificityEpitopesCessation Of LifeLeadCytokine
Grant awards (6)
Inhibition of CD38 NADase by anti-CD38 antibody: a novel therapy for systemic scleroderma$221,204
R43 · FY2020 · AR · contact PI
Development of an Frα x Frα x CD3 trivalent, biparatopic T-cell engaging antibody to treat high grade serous carcinoma$298,345
R43 · FY2019 · CA · contact PI
Bispecific Antibodies Directed to CD3and HBsAg to Treat Chronic Hepatitis B Virus$296,876
R43 · FY2019 · AI · contact PI
CD38 enzyme blocking heavy chain antibodies for Inflammatory Bowel Diseases$294,124
R43 · FY2019 · AI · contact PI
Development of a PSMA x PSMA x CD3 trivalent, bispecific T-cell engaging antibody to treat Castration Resistant Prostate Carcinoma$299,473
R43 · FY2018 · CA · contact PI
Development of novel heavy chain antibody-based therapeutics for polyomavirus infections$291,478
R43 · FY2018 · AI · contact PI